Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer-Reference-Cited by-同舟云学术

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer

Published:2021-11-06 Issue:2 Volume:111 Page:477-484
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Molenaar‐Kuijsten Laura¹,Braal C. Louwrens²,Groenland Stefanie L.³,Vries Niels¹,Rosing Hilde¹,Beijnen Jos H.¹⁴,Koolen Stijn L.W.²⁵,Vulink Annelie J.E.⁶,Dongen Marloes G.J.³,Mathijssen Ron H.J.²,Huitema Alwin D.R.¹⁷⁸,Steeghs Neeltje³,

Affiliation:

1. Department of Pharmacy & Pharmacology The Netherlands Cancer Institute – Antoni van Leeuwenhoek Amsterdam The Netherlands

2. Department of Medical Oncology Erasmus Medical Center Cancer Institute Rotterdam The Netherlands

3. Department of Clinical Pharmacology Division of Medical Oncology The Netherlands Cancer Institute – Antoni van Leeuwenhoek Amsterdam The Netherlands

4. Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands

5. Department of Hospital Pharmacy Erasmus University Medical Center Rotterdam The Netherlands

6. Department of Medical Oncology Reinier de Graaf Gasthuis Delft The Netherlands

7. Department of Clinical Pharmacy University Medical Center Utrecht University Utrecht The Netherlands

8. Department of Pharmacology Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2455

Reference32 articles.

1. US Food and Drug Administration Center for Drug Evaluation and Research. Palbociclib Clinical Pharmacology and Biopharmaceutics Review (2014).

2. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

3. European Medicines Agency Committee for Medicinal Products For Human Use (CHMP). Palbociclib European Public Assessment Report (2016).

4. Palbociclib and Letrozole in Advanced Breast Cancer

5. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments;Critical Reviews in Oncology/Hematology;2024-08

2. Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma;Cancer Letters;2024-07

3. Lipid Peroxidation via Regulating the Metabolism of Docosahexaenoic Acid and Arachidonic Acid in Autistic Behavioral Symptoms;Current Issues in Molecular Biology;2023-11-15

4. Targeting cyclin-dependent kinases in rheumatoid arthritis and psoriasis – a review of current evidence;Expert Opinion on Therapeutic Targets;2023-11-02

5. Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib;Frontiers in Pharmacology;2023-07-05